{"log_id": 8763153548645913305, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 4e-06, "average": 0.998769, "min": 0.991976}, "location": {"width": 456, "top": 156, "height": 32, "left": 180}, "words": "的受试者中也基本一致。老年患者无需调整剂量"}, {"probability": {"variance": 0.001012, "average": 0.987888, "min": 0.792183}, "location": {"width": 797, "top": 189, "height": 36, "left": 224}, "words": "肾功能不全者:在轻度(肌酐清除率50~80ml/min)、中度(肌酐清除率30~49m/min)"}, {"probability": {"variance": 0.002033, "average": 0.989652, "min": 0.69163}, "location": {"width": 846, "top": 226, "height": 37, "left": 183}, "words": "或重度(肌酐清除率10~29m/min)的肾功能不全的健康受试者中,多次服用80mg的非布"}, {"probability": {"variance": 0.00601, "average": 0.977755, "min": 0.480139}, "location": {"width": 844, "top": 263, "height": 37, "left": 185}, "words": "司他,与肾功能正常受试者(肌酐清除率大于80ml/min)相比,Cmax无变化,AUC与半衰"}, {"probability": {"variance": 0.001934, "average": 0.991135, "min": 0.716891}, "location": {"width": 850, "top": 300, "height": 38, "left": 181}, "words": "期增加,但肾功能不全的3组中,结果相似。肾功能不全者平均非布司他AUC值是正常者"}, {"probability": {"variance": 0.004599, "average": 0.980159, "min": 0.563102}, "location": {"width": 847, "top": 339, "height": 36, "left": 182}, "words": "的1.8倍,3种活性代谢物的平均Cmax和AUC分别增加到2倍和4倍。但是,肾功能不全"}, {"probability": {"variance": 7e-06, "average": 0.99817, "min": 0.990194}, "location": {"width": 730, "top": 377, "height": 36, "left": 184}, "words": "者的血清尿酸下降率与正常者类似(正常者是58%,重度肾功能不全者是55%"}, {"probability": {"variance": 7.3e-05, "average": 0.996845, "min": 0.946675}, "location": {"width": 805, "top": 414, "height": 36, "left": 224}, "words": "轻度至中度肾功能不全者的药物剂量无需调整。非布司他的推荐起始剂量为40mg,每"}, {"probability": {"variance": 0.001139, "average": 0.98942, "min": 0.792188}, "location": {"width": 849, "top": 451, "height": 36, "left": 181}, "words": "日一次。服用2周后血清尿酸未达到6mgdl以下者,推荐服用80mg。重度肾功能不全者数"}, {"probability": {"variance": 0.003049, "average": 0.979418, "min": 0.813953}, "location": {"width": 218, "top": 497, "height": 27, "left": 181}, "words": "据不充分,请谨慎使用"}, {"probability": {"variance": 1.7e-05, "average": 0.997368, "min": 0.982165}, "location": {"width": 576, "top": 527, "height": 36, "left": 228}, "words": "非布司他在肾功能损害末期需要进行透析的患者中未进行研究"}, {"probability": {"variance": 0.006265, "average": 0.968431, "min": 0.573292}, "location": {"width": 807, "top": 565, "height": 33, "left": 223}, "words": "肝功能不全:轻度(Chid- Pugh A级)或者中度( Child- Pugh B级):肝功能不全者,相"}, {"probability": {"variance": 0.001067, "average": 0.988162, "min": 0.85609}, "location": {"width": 446, "top": 604, "height": 32, "left": 182}, "words": "对于正常肝功能者,多次服用80mg的非布司他"}, {"probability": {"variance": 0.008636, "average": 0.951127, "min": 0.699423}, "location": {"width": 337, "top": 602, "height": 28, "left": 692}, "words": "与AUC24(总与离态)平均增加"}, {"probability": {"variance": 0.004751, "average": 0.970298, "min": 0.694687}, "location": {"width": 647, "top": 638, "height": 33, "left": 185}, "words": "了20%~30%。在不同的组别中,血清尿酸浓度下降率类似(健康组6"}, {"probability": {"variance": 0.066464, "average": 0.86716, "min": 0.351589}, "location": {"width": 100, "top": 632, "height": 32, "left": 928}, "words": "功能不全"}, {"probability": {"variance": 0.000558, "average": 0.992278, "min": 0.853604}, "location": {"width": 850, "top": 670, "height": 40, "left": 180}, "words": "组49%,中度肝功能不全组48%)。轻度与中度肝功能不全者的药物剂量无需调整。尚未"}, {"probability": {"variance": 0.008064, "average": 0.967605, "min": 0.540803}, "location": {"width": 686, "top": 709, "height": 36, "left": 181}, "words": "对重度肝功能损害者( child-pugh C级)进行研究,此类患者应谨慎使用"}, {"probability": {"variance": 0.015096, "average": 0.950517, "min": 0.409547}, "location": {"width": 742, "top": 747, "height": 33, "left": 224}, "words": "性别=多次口服非布司他,女性比男性的非布司他Cmax和AUC2分别高出30%和"}, {"probability": {"variance": 0.00404, "average": 0.98149, "min": 0.609394}, "location": {"width": 848, "top": 782, "height": 35, "left": 181}, "words": "然而进行体重矫正后,Cmax与AUC在两性别中相似此外,性别的血清尿酸浓度下降率"}, {"probability": {"variance": 7.4e-05, "average": 0.995882, "min": 0.968294}, "location": {"width": 388, "top": 821, "height": 31, "left": 183}, "words": "也相似。无需根据性别进行药物剂量调整"}, {"probability": {"variance": 0.000261, "average": 0.993535, "min": 0.924469}, "location": {"width": 474, "top": 856, "height": 31, "left": 225}, "words": "种族:尚未对不同种族进行特殊药代动力学的研究"}, {"probability": {"variance": 2e-05, "average": 0.996985, "min": 0.986798}, "location": {"width": 141, "top": 897, "height": 27, "left": 224}, "words": "药物相互作用:"}, {"probability": {"variance": 0.001077, "average": 0.983031, "min": 0.909948}, "location": {"width": 259, "top": 934, "height": 26, "left": 224}, "words": "非布司他对其它药物的影响"}, {"probability": {"variance": 0.008156, "average": 0.951392, "min": 0.626408}, "location": {"width": 802, "top": 966, "height": 32, "left": 226}, "words": "黄嘌呤氧化酶底物类药物-硫唑嘌呤、巯嘌呤和茶碱:非布司他是一个黄嘌呤氧化酶抑"}, {"probability": {"variance": 0.001047, "average": 0.992464, "min": 0.797328}, "location": {"width": 848, "top": 1002, "height": 34, "left": 181}, "words": "制剂。一项以健康受试者为试验对象、旨在评估本品对茶碱药代动力学影响的试验表明,本"}, {"probability": {"variance": 0.005807, "average": 0.982217, "min": 0.519324}, "location": {"width": 847, "top": 1039, "height": 35, "left": 181}, "words": "品与茶碱同时服用将导致尿中茶碱的主要代谢物之一1甲基黄嘌呤的含量增大400倍。由"}, {"probability": {"variance": 8.9e-05, "average": 0.994478, "min": 0.962757}, "location": {"width": 845, "top": 1076, "height": 33, "left": 183}, "words": "于人体长期暴露于1甲基黄嘌呤的安全性尚不明确,故非布司他与茶碱同时给药时应谨慎"}, {"probability": {"variance": 0.012009, "average": 0.952933, "min": 0.487225}, "location": {"width": 803, "top": 1112, "height": 33, "left": 225}, "words": "本品与通过黄嘌呤氧化酶代谢的药物(如硫唑嘌呤和巯嘌呤的相互作用未进行研究。本"}, {"probability": {"variance": 0.004243, "average": 0.97767, "min": 0.695422}, "location": {"width": 848, "top": 1148, "height": 35, "left": 181}, "words": "品对黄嘌呤氧化酶的抑制可能会导致这些药物血浆浓度升高,进而产生毒性。本品禁用于正"}, {"probability": {"variance": 0.00142, "average": 0.984582, "min": 0.808012}, "location": {"width": 578, "top": 1187, "height": 32, "left": 180}, "words": "在接受硫唑嘌呤、巯嘌呤治疗的患者[见禁忌和药物相互作用"}, {"probability": {"variance": 0.003376, "average": 0.981655, "min": 0.663577}, "location": {"width": 805, "top": 1223, "height": 32, "left": 223}, "words": "硫唑嘌呤和巯嘌呤通过三个主要代谢途径进行代谢,其中一个由黄嘌呤氧化酶介导。虽"}, {"probability": {"variance": 0.004265, "average": 0.982302, "min": 0.595668}, "location": {"width": 847, "top": 1260, "height": 31, "left": 180}, "words": "然未进行本品与硫唑嘌呤和巯嘌呤药物相互作用的研究,但是别嘌呤醇(一个黄嘌呤氧化酶"}, {"probability": {"variance": 0.002605, "average": 0.987356, "min": 0.673258}, "location": {"width": 847, "top": 1297, "height": 30, "left": 179}, "words": "抑制剂)与硫唑嘌呤或巯嘌呤同时给药已发现这些药物血药浓度有显著升高。因为本品是一"}, {"probability": {"variance": 0.000145, "average": 0.993207, "min": 0.946882}, "location": {"width": 844, "top": 1333, "height": 32, "left": 182}, "words": "个黄嘌呤氧化酶抑制剂,所以它可以抑制硫唑嘌呤和巯嘌呤由黄嘌呤氧化酶介导的代谢,导"}, {"probability": {"variance": 0.000155, "average": 0.994649, "min": 0.950062}, "location": {"width": 520, "top": 1372, "height": 30, "left": 178}, "words": "致硫唑嘌呤或巯嘌血药浓度升高,可能导致严重毒性"}, {"probability": {"variance": 0.005578, "average": 0.97705, "min": 0.569752}, "location": {"width": 795, "top": 1409, "height": 27, "left": 223}, "words": "P450底物药物:体外研究表明非布司他临床相关浓度时不会抑制P450酶CYP1A2、2C9"}, {"probability": {"variance": 0.001592, "average": 0.985669, "min": 0.744866}, "location": {"width": 847, "top": 1446, "height": 27, "left": 180}, "words": "2C19、2D6或3A4,它也不会诱导 CYPIA2、2B6、2C9、2C19或3A4。因此,本品与通过"}, {"probability": {"variance": 0.000151, "average": 0.996618, "min": 0.935511}, "location": {"width": 545, "top": 1482, "height": 28, "left": 181}, "words": "这些CYP酶代谢的药物之间不可能有药代动力学相互作用"}, {"probability": {"variance": 0.000603, "average": 0.9869, "min": 0.924078}, "location": {"width": 269, "top": 1522, "height": 25, "left": 222}, "words": "其它药物对非布司他的影响:"}, {"probability": {"variance": 0.000183, "average": 0.994474, "min": 0.928409}, "location": {"width": 804, "top": 1556, "height": 27, "left": 222}, "words": "非布司他通过多种代谢酶以结合和氧化两种方式代谢。每个酶亚型的相关作用还不清楚"}], "language": 3}